Citi keeps Buy rating for Protagonist Therapeutics stock

Published on 10/16/2026 at 04:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citi kept its Buy rating and set a USD 182.00 target on October 15, 2026. Protagonist Therapeutics stock reported USD 2.29 diluted earnings per share for April-June 2026.

Analyst support and upcoming results

Citi maintained its Buy rating on October 15, 2026.
Second-quarter revenue reached USD 213.48 million.
Protagonist Therapeutics is scheduled to report earnings on November 5, 2026.

PTGX, US74366E1029, Illustration mit AI erstellt.

Protagonist Therapeutics (ISIN US74366E1029) drew a fresh analyst signal on October 15, 2026, when Citi maintained its Buy rating and set a USD 182.00 price target, according to Markets Insider. The same report cited quarterly revenue of USD 213.48 million and net profit of USD 162.85 million for the quarter ended June 30, 2026.

Revenue sets a higher base

The second-quarter figures marked a sharp change from the prior-year comparison. Revenue rose from USD 5.55 million to USD 213.48 million, while GAAP net income moved from a USD 34.77 million loss to USD 162.85 million in the quarter ended June 30, 2026, according to Markets Insider. The result gives the analyst debate a concrete operating base rather than a pipeline story alone.

Three recent analyst steps

On October 12, 2026, UBS initiated coverage with a Buy rating and a USD 184.00 target, as reported by Markets Insider. On October 14, 2026, UBS was reported as upgrading its view to Strong Buy, while the consensus target stood at USD 154.44, according to MarketBeat. Citi's October 15, 2026 target therefore arrived after two other visible analyst developments.

What comes next for results?

The next scheduled earnings date is November 5, 2026, according to Ranked Stocks. For investors, that report will test whether the USD 213.48 million second-quarter revenue level carries into the next reporting period.

Nasdaq valuation context

Protagonist Therapeutics was last quoted at USD 136.55 on Nasdaq on October 15, 2026 at 4:00 p.m. ET. The finance snapshot showed a market capitalization of USD 8.8 billion, while the reported 52-week range was USD 73.08 to USD 160.81.